Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc.'s Q·Score is 5.1/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.2× debt-to-equity). Key area to monitor: currently unprofitable (-156% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for RCUS is $35.75, based on ratings from 12 Wall Street analysts. This is 46.9% above the current price of $24.33. Price targets are forward-looking estimates and not guarantees of future performance.

Arcus Biosciences, Inc. (RCUS) scores in line with sector averages on valuation metrics. The consensus analyst price target of $35.75 is 47% above the current price.

Arcus Biosciences, Inc.'s next earnings report is expected on approximately August 5, 2026.

Arcus Biosciences, Inc. has a net profit margin of -156.4%, indicating the company is currently operating at a net loss. Its gross margin stands at -121.6%, reflecting a more cost-intensive business model.

Arcus Biosciences, Inc. is reporting revenue declining 39.3% year-over-year.

Arcus Biosciences, Inc. has a debt-to-equity ratio of 0.22×, reflecting a very low debt-to-equity ratio, signalling a conservatively financed balance sheet. Its current ratio is 4.04×, indicating comfortable short-term liquidity.